NOTICE OF INTENT TO SOLE SOURCE - Psomagen, Inc. GEM-X Cell QC, sequencing and data analysis
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NIH NCI
Contract Value
Not provided
Codes & Classification
Solicitation Number
PCA-NCI-09798
NAICS
541990 - All Other Professional, Scientific, and Technical Services
Classification Code
AJ11
Additional Details
Documents1
The National Cancer Institute (NCI), a division of the National Institutes of Health (NIH) under the Department of Health and Human Services, has issued a Special Notice indicating its intent to award a sole source contract to Psomagen, Inc., located at 1330 Piccard Dr., Suite 103, Rockville, MD 20850-4372. This procurement, identified under PCA-NCI-09798, is for the provision of GEM-X Cell quality control (QC), sequencing, and data analysis services in support of ongoing research studies involving clinical xenograft biosamples.
The primary purpose of this procurement is to ensure the continuity and consistency of data for ongoing studies by utilizing Psomagen, Inc.’s proprietary GEM-X Cell testing platform. The scope of work includes quality control of submitted single cell samples, generation of sequencing libraries using the 10X Chromium GEM-X Single Cell 5p RNA technology, and comprehensive expression analysis of frozen clinical xenograft biosamples. These services are critical for maintaining the integrity of the research, as the biosamples are irreplaceable and have a limited viability window, requiring transport times of no more than two hours.
The intended outcome is to obtain high-quality, consistent sequencing and expression data that aligns with prior datasets generated in the course of these studies. This continuity is essential for the validity of ongoing research and for drawing meaningful scientific conclusions.
Key requirements for this procurement include:
- Proven capability to perform quality control on single cell samples with minimal transport time.
- Expertise in generating sequencing libraries using the 10X Chromium GEM-X Single Cell 5p RNA platform.
- Ability to deliver expression analysis data compatible with existing datasets from Psomagen, Inc.
- Capacity to integrate seamlessly with established Psomagen workflows and data formats.
The procurement is classified under NAICS code 541990 (All Other Professional, Scientific, and Technical Services) and Product Service Code AJ11. There are no set-aside requirements for this opportunity.
While this notice is not a solicitation for proposals, the Government invites interested vendors who believe they can fully meet the stated requirements to submit a capabilities statement, including relevant past performance, to the designated point of contact. Interested parties must specifically address the challenge of integrating with Psomagen’s proprietary quality control, sequencing, and data analysis processes. All responses will be evaluated solely to determine whether to proceed with a competitive procurement. The statutory authority for this sole source action is 41 U.S.C. 3204(b)(2), as implemented by FAR 12.102(a), which allows for other-than-full-and-open competition when only one source is available.
The place of performance for this contract is Rockville, Maryland, United States. The contracting office is the NIH NCI, and the primary point of contact for this notice is Christine Biser, who can be reached via email at [email protected]. Interested vendors must submit their capability statements by 12:00 pm Eastern Daylight Time on Wednesday, September 24, 2026. Late submissions will be handled in accordance with FAR 52.212-1(f).
For further details or to view the official notice, contractors may refer to the SAM.gov opportunity at https://sam.gov/opp/f184b03516d54426a93beeec8de069e2/view.
This notice remains active and all responsible sources capable of providing comparable services are encouraged to respond as outlined above.